Summary

Changes in National Insurance Reimbursement with Introduction of the DPC Package Payment System for ¹³¹I Therapy for Hyperthyroidism

Sadahiro Watanabe,* Shigeru Kosuda,* Fuzuki Yano,* Katsumi Abe,* Shoichi Kusano* and Yuji Tanaka**

*Department of Radiology, National Defense Medical College **Third Department of Internal Medicine, National Defense Medical College

The inpatient DPC package payment system lowers national insurance reimbursement as compared to the former fee-for-service payment system for inpatients, when an inpatient with hyperthyroidism or toxic multinodular goiter (TMNG) is admitted for 2-day radioiodine therapy. The differentials are ¥29,970 and ¥48,870 for a 2-day hospital stay for administration of

555 MBq and 925 MBq, respectively. We request the Health and Labor Ministry to newly establish the fee for ¹³¹I internal therapy for hyperthyroidism. Furthermore, the fee should be paid according to the fee-forservice payment system.

Key words: Radioiodine therapy, Hyperthyroidism, Toxic multinodular goiter.